Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Janne Backman

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Concepts & Ideas

Physiology

Drug Interactions

Chemicals & Drugs

Anatomy

Liver Microsomes

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
93
Neuvonen, Pertti
32
Niemi, Mikko
31
Kivistö, Kari
30
Neuvonen, Mikko
18
Laitila, Jouko
14
Wang, Jun-Sheng
9
Olkkola, Klaus
9
Kajosaari, Lauri
8
Wen, Xia
7
Lilja, Jari
7
Kyrklund, Carl
7
Granfors, Marika
6
Tornio, Aleksi
5
Pasanen, Marja
5
Fritz, Peter

Sign-in to see all Coauthors

Publications

TOP 3
Keskitalo Jenni E; Kurkinen Kaisa J; Neuvonen Mikko; Backman Janne T; Neuvonen Pertti J; Niemi Mikko
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
Xiang Xiaoqiang; Han Yi; Neuvonen Mikko; Pasanen Marja K; Kalliokoski Annikka; Backman Janne T; Laitila Jouko; Neuvonen Pertti J; Niemi Mikko
Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Shyamsundar Murali; McKeown Scott T W; O'Kane Cecilia M; Craig Thelma R; Brown Vanessa; Thickett David R; Matthay Michael A; Taggart Clifford C; Backman Janne T; Elborn J Stuart; McAuley Daniel F
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Janne Backman (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Keskitalo Jenni E; Kurkinen Kaisa J; Neuvonen Mikko; Backman Janne T; Neuvonen Pertti J; Niemi Mikko
No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.
British journal of clinical pharmacology 2009;68(2):207-13.
2009: Xiang Xiaoqiang; Han Yi; Neuvonen Mikko; Pasanen Marja K; Kalliokoski Annikka; Backman Janne T; Laitila Jouko; Neuvonen Pertti J; Niemi Mikko
Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans.
Pharmacogenetics and genomics 2009;19(6):447-57.
2009: Shyamsundar Murali; McKeown Scott T W; O'Kane Cecilia M; Craig Thelma R; Brown Vanessa; Thickett David R; Matthay Michael A; Taggart Clifford C; Backman Janne T; Elborn J Stuart; McAuley Daniel F
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers.
American journal of respiratory and critical care medicine 2009;179(12):1107-14.
2008: Kalliokoski Annikka; Backman Janne T; Neuvonen Pertti J; Niemi Mikko
Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide.
Pharmacogenetics and genomics 2008;18(11):937-42.
2008: Kalliokoski A; Backman J T; Kurkinen K J; Neuvonen P J; Niemi M
Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism.
Clinical pharmacology and therapeutics 2008;84(4):488-96.
2008: Tornio A; Niemi M; Neuvonen M; Laitila J; Kalliokoski A; Neuvonen P J; Backman J T
The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo.
Clinical pharmacology and therapeutics 2008;84(3):403-11.
2008: Karjalainen Marjo J; Neuvonen Pertti J; Backman Janne T
In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
Basic & clinical pharmacology & toxicology 2008;103(2):157-65.
2008: Karjalainen Marjo J; Neuvonen Pertti J; Backman Janne T
Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.
European journal of clinical pharmacology 2008;64(5):511-9.
2008: Fanta Samuel; Niemi Mikko; Jönsson Siv; Karlsson Mats O; Holmberg Christer; Neuvonen Pertti J; Hoppu Kalle; Backman Janne T
Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms.
Pharmacogenetics and genomics 2008;18(2):77-90.
2008: Backman Janne T; Schröder Marika T; Neuvonen Pertti J
Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine.
European journal of clinical pharmacology 2008;64(1):17-24.
2008: Tornio Aleksi; Niemi Mikko; Neuvonen Pertti J; Backman Janne T
Trimethoprim and the CYP2C8*3 allele have opposite effects on the pharmacokinetics of pioglitazone.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(1):73-80.
2008: Neuvonen Pertti J; Backman Janne T; Niemi Mikko
Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Clinical pharmacokinetics 2008;47(7):463-74.
2007: Fanta S; Jönsson S; Backman J T; Karlsson M O; Hoppu K
Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates.
British journal of clinical pharmacology 2007;64(6):772-84.
2007: Karjalainen Marjo J; Neuvonen Pertti J; Backman Janne T
Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.
European journal of clinical pharmacology 2007;63(9):829-36.
2007: Lilja J J; Backman J T; Neuvonen P J
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam--probes of CYP2C9, CYP1A2, and CYP3A4.
Clinical pharmacology and therapeutics 2007;81(6):833-9.
2007: Tornio Aleksi; Niemi Mikko; Neuvonen Pertti J; Backman Janne T
Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen.
European journal of clinical pharmacology 2007;63(5):463-9.
2006: Neuvonen Pertti J; Niemi Mikko; Backman Janne T
Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Clinical pharmacology and therapeutics 2006;80(6):565-81.
2006: Karjalainen Marjo J; Neuvonen Pertti J; Backman Janne T
Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in vitro prediction of drug interactions.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(12):2091-6.
2006: Niemi Mikko; Arnold Katja A; Backman Janne T; Pasanen Marja K; Gödtel-Armbrust Ute; Wojnowski Leszek; Zanger Ulrich M; Neuvonen Pertti J; Eichelbaum Michel; Kivistö Kari T; Lang Thomas
Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics.
Pharmacogenetics and genomics 2006;16(11):801-8.
2006: Backman Janne T; Karjalainen Marjo J; Neuvonen Mikko; Laitila Jouko; Neuvonen Pertti J
Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects.
British journal of clinical pharmacology 2006;62(3):345-57.
2006: Backman J T; Kajosaari L I; Niemi M; Neuvonen P J
Cyclosporine A increases plasma concentrations and effects of repaglinide.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2006;6(9):2221-2.
2006: Tornio Aleksi; Neuvonen Pertti J; Backman Janne T
The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone.
European journal of clinical pharmacology 2006;62(8):645-51.
2006: Jaakkola Tiina; Laitila Jouko; Neuvonen Pertti J; Backman Janne T
Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.
Basic & clinical pharmacology & toxicology 2006;99(1):44-51.
2006: Jaakkola Tiina; Backman Janne T; Neuvonen Mikko; Niemi Mikko; Neuvonen Pertti J
Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone.
European journal of clinical pharmacology 2006;62(7):503-9.
2006: Niemi Mikko; Tornio Aleksi; Pasanen Marja K; Fredrikson Hanna; Neuvonen Pertti J; Backman Janne T
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide.
European journal of clinical pharmacology 2006;62(6):463-72.
2006: Backman Janne T; Granfors Marika T; Neuvonen Pertti J
Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine.
European journal of clinical pharmacology 2006;62(6):451-61.
2006: Pasanen Marja K; Backman Janne T; Neuvonen Pertti J; Niemi Mikko
Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population.
European journal of clinical pharmacology 2006;62(6):409-15.
2006: Kajosaari Lauri I; Niemi Mikko; Backman Janne T; Neuvonen Pertti J
Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide.
Clinical pharmacology and therapeutics 2006;79(3):231-42.
2006: Kajosaari Lauri I; Jaakkola Tiina; Neuvonen Pertti J; Backman Janne T
Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide.
European journal of clinical pharmacology 2006;62(3):217-23.
2006: Lepäntalo Aino; Mikkelsson Jussi; Reséndiz Julio C; Viiri Leena; Backman Janne T; Kankuri Esko; Karhunen Pekka J; Lassila Riitta
Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
Thrombosis and haemostasis 2006;95(2):253-9.
2006: Granfors Marika T; Wang Jun-Sheng; Kajosaari Lauri I; Laitila Jouko; Neuvonen Pertti J; Backman Janne T
Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro.
Basic & clinical pharmacology & toxicology 2006;98(1):79-85.
2006: Jaakkola Tiina; Backman Janne T; Neuvonen Mikko; Laitila Jouko; Neuvonen Pertti J
Effect of rifampicin on the pharmacokinetics of pioglitazone.
British journal of clinical pharmacology 2006;61(1):70-8.
2005: Lilja Jari J; Backman Janne T; Neuvonen Pertti J
Effect of itraconazole on the pharmacokinetics of atenolol.
Basic & clinical pharmacology & toxicology 2005;97(6):395-8.
2005: Granfors Marika T; Backman Janne T; Laitila Jouko; Neuvonen Pertti J
Oral contraceptives containing ethinyl estradiol and gestodene markedly increase plasma concentrations and effects of tizanidine by inhibiting cytochrome P450 1A2.
Clinical pharmacology and therapeutics 2005;78(4):400-11.
2005: Kajosaari Lauri I; Niemi Mikko; Neuvonen Mikko; Laitila Jouko; Neuvonen Pertti J; Backman Janne T
Cyclosporine markedly raises the plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics 2005;78(4):388-99.
2005: Kajosaari Lauri I; Laitila Jouko; Neuvonen Pertti J; Backman Janne T
Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.
Basic & clinical pharmacology & toxicology 2005;97(4):249-56.
2005: Backman Janne T; Luurila Harri; Neuvonen Mikko; Neuvonen Pertti J
Rifampin markedly decreases and gemfibrozil increases the plasma concentrations of atorvastatin and its metabolites.
Clinical pharmacology and therapeutics 2005;78(2):154-67.
2005: Niemi Mikko; Backman Janne T; Juntti-Patinen Laura; Neuvonen Mikko; Neuvonen Pertti J
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide.
British journal of clinical pharmacology 2005;60(2):208-17.
2005: Tornio Aleksi; Pasanen Marja K; Laitila Jouko; Neuvonen Pertti J; Backman Janne T
Comparison of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) as inhibitors of cytochrome P450 2C8.
Basic & clinical pharmacology & toxicology 2005;97(2):104-8.
2005: Niemi Mikko; Backman Janne T; Kajosaari Lauri I; Leathart Julian B; Neuvonen Mikko; Daly Ann K; Eichelbaum Michel; Kivistö Kari T; Neuvonen Pertti J
Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
Clinical pharmacology and therapeutics 2005;77(6):468-78.
2005: Jaakkola Tiina; Backman Janne T; Neuvonen Mikko; Neuvonen Pertti J
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone.
Clinical pharmacology and therapeutics 2005;77(5):404-14.
2005: Niemi Mikko; Neuvonen Pertti J; Hofmann Ute; Backman Janne T; Schwab Matthias; Lütjohann Dieter; von Bergmann Klaus; Eichelbaum Michel; Kivistö Kari T
Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17.
Pharmacogenetics and genomics 2005;15(5):303-9.
2005: Fanta Samuel; Backman Janne T; Seikku Paula; Holmberg Christer; Hoppu Kalle
Cyclosporine A monitoring--how to account for twice and three times daily dosing.
Pediatric nephrology (Berlin, Germany) 2005;20(5):591-6.
2005: Lilja Jari J; Backman Janne T; Neuvonen Pertti J
Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of racemic warfarin in healthy subjects.
British journal of clinical pharmacology 2005;59(4):433-9.
2004: Granfors Marika T; Backman Janne T; Neuvonen Mikko; Neuvonen Pertti J
Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism.
Clinical pharmacology and therapeutics 2004;76(6):598-606.
2004: Kajosaari Lauri I; Backman Janne T; Neuvonen Mikko; Laitila Jouko; Neuvonen Pertti J
Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.
British journal of clinical pharmacology 2004;58(4):390-6.
2004: Niemi Mikko; Backman Janne T; Neuvonen Pertti J
Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone.
Clinical pharmacology and therapeutics 2004;76(3):239-49.
2004: Niemi Mikko; Schaeffeler Elke; Lang Thomas; Fromm Martin F; Neuvonen Mikko; Kyrklund Carl; Backman Janne T; Kerb Reinhold; Schwab Matthias; Neuvonen Pertti J; Eichelbaum Michel; Kivistö Kari T
High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1).
Pharmacogenetics 2004;14(7):429-40.
2004: Granfors Marika T; Backman Janne T; Neuvonen Mikko; Ahonen Jouni; Neuvonen Pertti J
Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction.
Clinical pharmacology and therapeutics 2004;75(4):331-41.
2004: Niemi Mikko; Kajosaari Lauri I; Neuvonen Mikko; Backman Janne T; Neuvonen Pertti J
The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects.
British journal of clinical pharmacology 2004;57(4):441-7.
2004: Granfors Marika T; Backman Janne T; Laitila Jouko; Neuvonen Pertti J
Tizanidine is mainly metabolized by cytochrome p450 1A2 in vitro.
British journal of clinical pharmacology 2004;57(3):349-53.
2004: Kyrklund Carl; Backman Janne T; Neuvonen Mikko; Neuvonen Pertti J
Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.
British journal of clinical pharmacology 2004;57(2):181-7.
2003: Niemi Mikko; Leathart Julian B; Neuvonen Mikko; Backman Janne T; Daly Ann K; Neuvonen Pertti J
Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide.
Clinical pharmacology and therapeutics 2003;74(4):380-7.
2003: Niemi Mikko; Backman Janne T; Neuvonen Mikko; Neuvonen Pertti J
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects.
British journal of clinical pharmacology 2003;56(4):427-32.
2003: Niemi M; Backman J T; Granfors M; Laitila J; Neuvonen M; Neuvonen P J
Gemfibrozil considerably increases the plasma concentrations of rosiglitazone.
Diabetologia 2003;46(10):1319-23.
2003: Niemi Mikko; Neuvonen Mikko; Juntti-Patinen Laura; Backman Janne T; Neuvonen Pertti J
Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide.
Clinical pharmacology and therapeutics 2003;74(1):25-31.
2003: Kyrklund Carl; Backman Janne T; Neuvonen Mikko; Neuvonen Pertti J
Gemfibrozil increases plasma pravastatin concentrations and reduces pravastatin renal clearance.
Clinical pharmacology and therapeutics 2003;73(6):538-44.
2003: Niemi M; Backman J T; Neuvonen M; Neuvonen P J
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide.
Diabetologia 2003;46(3):347-51.
2003: Lilja Jari J; Backman Janne T; Laitila Jouko; Luurila Harri; Neuvonen Pertti J
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol.
Clinical pharmacology and therapeutics 2003;73(3):192-8.
2003: Niemi Mikko; Backman Janne T; Fromm Martin F; Neuvonen Pertti J; Kivistö Kari T
Pharmacokinetic interactions with rifampicin : clinical relevance.
Clinical pharmacokinetics 2003;42(9):819-50.
2002: Backman Janne T; Kyrklund Carl; Neuvonen Mikko; Neuvonen Pertti J
Gemfibrozil greatly increases plasma concentrations of cerivastatin.
Clinical pharmacology and therapeutics 2002;72(6):685-91.
2002: Wang Jun-Sheng; Neuvonen Mikko; Wen Xia; Backman Janne T; Neuvonen Pertti J
Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(12):1352-6.
2002: Sperker Bernhard; Mürdter Thomas E; Backman Janne T; Fritz Peter; Kroemer Heyo K
Expression of active human beta-glucuronidase in Sf9 cells infected with recombinant baculovirus.
Life sciences 2002;71(13):1547-57.
2002: Wang Jun-Sheng; Wen Xia; Backman Janne T; Neuvonen Pertti J
Effect of albumin and cytosol on enzyme kinetics of tolbutamide hydroxylation and on inhibition of CYP2C9 by gemfibrozil in human liver microsomes.
The Journal of pharmacology and experimental therapeutics 2002;302(1):43-9.
2002: Wen Xia; Wang Jun-Sheng; Backman Janne T; Laitila Jouko; Neuvonen Pertti J
Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively.
Drug metabolism and disposition: the biological fate of chemicals 2002;30(6):631-5.
2002: Mürdter Thomas E; Friedel Godehard; Backman Janne T; McClellan Monika; Schick Monika; Gerken Manfred; Bosslet Klaus; Fritz Peter; Toomes Heikki; Kroemer Heyo K; Sperker Bernhard
Dose optimization of a doxorubicin prodrug (HMR 1826) in isolated perfused human lungs: low tumor pH promotes prodrug activation by beta-glucuronidase.
The Journal of pharmacology and experimental therapeutics 2002;301(1):223-8.
2002: Wen Xia; Wang Jun-Sheng; Neuvonen Pertti J; Backman Janne T
Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.
European journal of clinical pharmacology 2002;57(11):799-804.
2001: Wen X; Wang J S; Kivistö K T; Neuvonen P J; Backman J T
In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
British journal of clinical pharmacology 2001;52(5):547-53.
2001: Wen X; Wang J S; Backman J T; Kivistö K T; Neuvonen P J
Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(11):1359-61.
2001: Villikka K; Varis T; Backman J T; Neuvonen P J; Kivistö K T
Effect of methylprednisolone on CYP3A4-mediated drug metabolism in vivo.
European journal of clinical pharmacology 2001;57(6-7):457-60.
2001: Niemi M; Backman J T; Neuvonen M; Neuvonen P J; Kivistö K T
Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide.
Clinical pharmacology and therapeutics 2001;69(6):400-6.
2001: Kyrklund C; Backman J T; Kivistö K T; Neuvonen M; Laitila J; Neuvonen P J
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
Clinical pharmacology and therapeutics 2001;69(5):340-5.
2001: Kivistö K T; Wang J S; Backman J T; Nyman L; Taavitsainen P; Anttila M; Neuvonen P J
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole.
European journal of clinical pharmacology 2001;57(1):37-42.
2001: Niemi M; Backman J T; Neuvonen M; Laitila J; Neuvonen P J; Kivistö K T
Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride.
Clinical pharmacology and therapeutics 2001;69(4):194-200.
2000: Kyrklund C; Backman J T; Kivistö K T; Neuvonen M; Laitila J; Neuvonen P J
Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations.
Clinical pharmacology and therapeutics 2000;68(6):592-7.
2000: Niemi M; Kivistö K T; Backman J T; Neuvonen P J
Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride.
British journal of clinical pharmacology 2000;50(6):591-5.
2000: Wang J S; Backman J T; Kivistö K T; Neuvonen P J
Effects of metronidazole on midazolam metabolism in vitro and in vivo.
European journal of clinical pharmacology 2000;56(8):555-9.
2000: Niemi M; Backman J T; Neuvonen M; Neuvonen P J; Kivistö K T
Rifampin decreases the plasma concentrations and effects of repaglinide.
Clinical pharmacology and therapeutics 2000;68(5):495-500.
2000: Varis T; Kivistö K T; Backman J T; Neuvonen P J
The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect.
Clinical pharmacology and therapeutics 2000;68(5):487-94.
2000: Lilja J J; Kivistö K T; Backman J T; Neuvonen P J
Effect of grapefruit juice dose on grapefruit juice-triazolam interaction: repeated consumption prolongs triazolam half-life.
European journal of clinical pharmacology 2000;56(5):411-5.
2000: Backman J T; Kyrklund C; Kivistö K T; Wang J S; Neuvonen P J
Plasma concentrations of active simvastatin acid are increased by gemfibrozil.
Clinical pharmacology and therapeutics 2000;68(2):122-9.
2000: Wang J S; Backman J T; Taavitsainen P; Neuvonen P J; Kivistö K T
Involvement of CYP1A2 and CYP3A4 in lidocaine N-deethylation and 3-hydroxylation in humans.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(8):959-65.
2000: Kantola T; Backman J T; Niemi M; Kivistö K T; Neuvonen P J
Effect of fluconazole on plasma fluvastatin and pravastatin concentrations.
European journal of clinical pharmacology 2000;56(3):225-9.
2000: Backman J T; Mäenpää J; Belle D J; Wrighton S A; Kivistö K T; Neuvonen P J
Lack of correlation between in vitro and in vivo studies on the effects of tangeretin and tangerine juice on midazolam hydroxylation.
Clinical pharmacology and therapeutics 2000;67(4):382-90.
2000: Varis T; Backman J T; Kivistö K T; Neuvonen P J
Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methylprednisolone.
Clinical pharmacology and therapeutics 2000;67(3):215-21.
1999: Wang J S; Backman J T; Wen X; Taavitsainen P; Neuvonen P J; Kivistö K T
Fluvoxamine is a more potent inhibitor of lidocaine metabolism than ketoconazole and erythromycin in vitro.
Pharmacology & toxicology 1999;85(5):201-5.
1999: Kivistö K T; Lilja J J; Backman J T; Neuvonen P J
Repeated consumption of grapefruit juice considerably increases plasma concentrations of cisapride.
Clinical pharmacology and therapeutics 1999;66(5):448-53.
1999: Backman J T; Siegle I; Zanger U M; Fritz P
Immunohistochemical detection of microsomal epoxide hydrolase in human synovial tissue.
The Histochemical journal 1999;31(10):645-9.
1999: Wang J S; Wen X; Backman J T; Taavitsainen P; Neuvonen P J; Kivistö K T
Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
Pharmacology & toxicology 1999;85(4):157-61.
1999: Backman J T; Wang J S; Wen X; Kivistö K T; Neuvonen P J
Mibefradil but not isradipine substantially elevates the plasma concentrations of the CYP3A4 substrate triazolam.
Clinical pharmacology and therapeutics 1999;66(4):401-7.
1999: Varis T; Kivistö K T; Backman J T; Neuvonen P J
Itraconazole decreases the clearance and enhances the effects of intravenously administered methylprednisolone in healthy volunteers.
Pharmacology & toxicology 1999;85(1):29-32.
1998: Lilja J J; Kivistö K T; Backman J T; Lamberg T S; Neuvonen P J
Grapefruit juice substantially increases plasma concentrations of buspirone.
Clinical pharmacology and therapeutics 1998;64(6):655-60.
1998: Backman J T; Siegle I; Fritz P
Immunohistochemical localization of metallothionein in synovial tissue of patients with chronic inflammatory and degenerative joint disease.
Virchows Archiv : an international journal of pathology 1998;433(2):153-60.
1998: Backman J T; Kivistö K T; Olkkola K T; Neuvonen P J
The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin.
European journal of clinical pharmacology 1998;54(1):53-8.
1998: Siegle I; Klein T; Backman J T; Saal J G; Nüsing R M; Fritz P
Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases.
Arthritis and rheumatism 1998;41(1):122-9.
1997: Sperker B; Backman J T; Kroemer H K
The role of beta-glucuronidase in drug disposition and drug targeting in humans.
Clinical pharmacokinetics 1997;33(1):18-31.
1997: Villikka K; Kivistö K T; Backman J T; Olkkola K T; Neuvonen P J
Triazolam is ineffective in patients taking rifampin.
Clinical pharmacology and therapeutics 1997;61(1):8-14.
1996: Backman J T; Olkkola K T; Ojala M; Laaksovirta H; Neuvonen P J
Concentrations and effects of oral midazolam are greatly reduced in patients treated with carbamazepine or phenytoin.
Epilepsia 1996;37(3):253-7.
1996: Backman J T; Olkkola K T; Neuvonen P J
Rifampin drastically reduces plasma concentrations and effects of oral midazolam.
Clinical pharmacology and therapeutics 1996;59(1):7-13.
1995: Backman J T; Olkkola K T; Neuvonen P J
Azithromycin does not increase plasma concentrations of oral midazolam.
International journal of clinical pharmacology and therapeutics 1995;33(6):356-9.
1994: Aranko K; Luurila H; Backman J T; Neuvonen P J; Olkkola K T
The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone.
British journal of clinical pharmacology 1994;38(4):363-7.
1994: Olkkola K T; Backman J T; Neuvonen P J
Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole.
Clinical pharmacology and therapeutics 1994;55(5):481-5.
1994: Backman J T; Olkkola K T; Aranko K; Himberg J J; Neuvonen P J
Dose of midazolam should be reduced during diltiazem and verapamil treatments.
British journal of clinical pharmacology 1994;37(3):221-5.
1994: Backman J T; Aranko K; Himberg J J; Olkkola K T
A pharmacokinetic interaction between roxithromycin and midazolam.
European journal of clinical pharmacology 1994;46(6):551-5.

Sign-in to see more